NASDAQ: PBLAPanbela Therapeutics Inc Stock
$0.51+0.02 (+4.08%)
Updated Mar 24, 2023
PBLA Price
$0.51
Fair Value Price
$2.05
Market Cap
$7.44M
52 Week Low
$0.41
52 Week High
$87.60
P/E
-0.01x
P/B
-0.92x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.62
Operating Cash Flow
-$15M
Beta
0.25
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PBLA Overview
Panbela Therapeutics, Inc. is a biopharmaceutical company developing disruptive treatments for patients with cancer. It focuses on pancreatic cancer, colorectal cancer, and ovarian cancer. The company's lead product candidate, SBP-101, is in Phase Ia/Ib clinical trial for the treatment of metastatic pancreatic ductal adenocarcinoma. Panbela Therapeutics was incorporated in 2011 and is headquartered in Waconia, MN.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PBLA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBLA ($0.51) is undervalued by 75.16% relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PBLA ($0.51) is significantly undervalued by 75.16% relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PBLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PBLA due diligence checks available for Premium users.
Be the first to know about important PBLA news, forecast changes, insider trades & much more!
PBLA News
Valuation
PBLA fair value
Fair Value of PBLA stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$2.05
Undervalued by
75.16%
PBLA ($0.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBLA ($0.51) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PBLA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
17.88x
Market
21.37x
PBLA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.92x
Industry
4.89x
PBLA's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.7M
Profit Margin
0%
PBLA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.0M
Liabilities
$13.0M
Debt to equity
-1.62
PBLA's short-term liabilities ($7.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBLA's long-term liabilities ($5.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBLA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBLA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
$0.0
Financing
$5.3M
PBLA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PBLA vs Biotech Stocks
Panbela Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.